Lake Street Downgrades Brickell Biotech to Hold

Lake Street analyst Thomas Flaten downgrades Brickell Biotech (NASDAQ:BBI) from Buy to Hold.

Lake Street analyst Thomas Flaten downgrades Brickell Biotech (NASDAQ:BBI) from Buy to Hold.

Total
0
Shares
Related Posts